Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Shares of Hikma Pharmaceuticals PLC HIK inched up 0.33% to £18.37 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.65% to ...

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...

This might drive the stock higher in the near term. Hikma Pharmaceuticals ( LON:HIK ) First Half 2024 Results Key Financial Results Revenue: US$1.57b (up 10.0% from 1H... Shares of Hikma ...

Shares of Hikma Pharmaceuticals PLC HIK rallied 1.64% to £18.01 Thursday, on what proved to be an all-around poor trading ...

Hikma Pharmaceuticals Usa Inc was founded in 2011 and operates in Eatontown, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

Hikma Pharmaceuticals reiterated its full-year outlook on Thursday on the back of strong trading across the business.

Ionis Pharmaceuticals exceeded revenue estimates by 3.4%, reporting $134 million against a $129.57 million expectation. Spinraza royalties decreased by $10 million year over year to $57 million ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...